Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 12 April 2017, 10:00 - 16:00.

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens Present for all notes
2. Mr Michael Chambers Present for all notes
3. Mr David Chandler Present for all notes
4. Gail Coster Present for all notes
5. Dr Prithviraj Das Present for notes 29 - 52
6. Mr John P Hampson Present for all notes
7. Dr Nigel Langford Present for all notes
8. Dr Iain Miller Present for all notes
9. Professor Eugene Milne Present for all notes
10. Professor Stephen O’Brien Present for all notes
11. Sarah Parry Present for all notes
12. Pamela Rees Present for all notes
13. Professor Peter Selby Present for all notes
14. Professor Matt Stevenson Present for notes 17 – 64
15. Dr Paul Tappenden Present for all notes
16. Nigel Westwood Present for all notes
17. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Kate Moore Project Manager, National Institute for Health and Care Excellence Present for all notes

Mandy Tonkinson Administrator, National Institute for Health and Care Excellence Present for notes 1 – 40
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Presented</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Richards</td>
<td>Assistant Project Manager, National Institute for Health and Care Excellence</td>
<td>41 - 64</td>
</tr>
<tr>
<td>Hamish Lunagaria</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Martyn Burke</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Ian Watson</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Abitha Senthinathan</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>17 – 28</td>
</tr>
<tr>
<td>Alexandra Filby</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>17 – 28</td>
</tr>
<tr>
<td>Anna Brett</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>29 – 40</td>
</tr>
<tr>
<td>Nicola Hay</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>29 – 40</td>
</tr>
<tr>
<td>Henry Edwards</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>41 - 64</td>
</tr>
</tbody>
</table>

**Non-public attendees:**
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of carfilzomib for treated multiple myeloma, adalimumab and dexamethasone for treating non-infectious uveitis, nivolumab for relapsed or refractory classical Hodgkin lymphoma, nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy and nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

2. The Chair informed the Committee of the non-public observers at this meeting: Dominic Bradshaw, Steve Estevao, Karyo Angeloudis, Leslie Hays, Christopher Eatough and Lee Walker.

3. Apologies were received from Professor Kathryn Abel, Kamal Balakrishnan Professor Andrea Manca, Professor Andrew Renehan, and Robert Walton.

Any other Business

4. None

Appraisal of Carfilzomib for treated multiple myeloma [ID934]
Part 1 – Open session
5. The Chair welcomed the invited experts: Peter Cain, Peter Clark and Charlotta Karna to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Amgen to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Mr Michael Chambers, Mr David Chandler, Gail Coster, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Professor Eugene Milne, Professor Stephen O’Brien, Sarah Parry, Pamela Rees, Dr Peter Selby, Dr Paul Tappenden, Nigel Westwood and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

7.2. Professor Stephen O’Brien declared a non-personal non-specific financial interest as his University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer, Novartis and Bristol-Myers Squibb

9.2.1 It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

7.3. Professor Matt Stevenson is conflicted as he declared a personal specific financial interest. He has received payment from by Onyx who previously held the rights to carfilzomib to comment on their STA submission. Onyx were then taken over by Amgen and he has done no further work.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of carfilzomib for treated multiple myeloma.

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of adalimumab and dexamethasone for treating non-infectious uveitis [ID763]

Part 1 – Open session

17. The Chair welcomed the invited experts: Inigo Bermejo and Hazel Squires to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from AbbVie and Allergan to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Mr Michael Chambers, Mr David Chandler, Gail Coster, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Professor Eugene Milne, Professor Stephen O’Brien, Sarah Parry, Pamela Rees, Dr Peter Selby, Professor Matt Stevenson, Nigel Westwood and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab and dexamethasone for treating non-infectious uveitis.

19.2. Dr Paul Tappenden declared a non-personal specific financial interest as he provided an internal peer review of the Assessment Group report, although he had not been directly involved.

19.2.1. It was agreed that this declaration would not prevent Dr Paul Tappenden from participating in this section of the meeting.
19.3 Dr Prithwiraj Das is conflicted as he declared that his organisation (Boehringer Ingelheim) has a biosimilar to adalimumab in the pipeline.

20. The Chair asked all NICE Staff to declare any relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab and dexamethasone for treating non-infectious uveitis.

21. The Chair asked all other invited guests (assessment group and invited experts, not including observers) to declare their relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab and dexamethasone for treating non-infectious uveitis.

22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.

27. The Committee continued to discuss the clinical and cost effectiveness of adalimumab and dexamethasone for treating non-infectious uveitis.

27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of nivolumab for relapsed or refractory classical Hodgkin lymphoma [ID972]
Part 1 – Open session

29. The Chair welcomed the invited experts: Peter Clark, Jo Picot and Micah Rose to the meeting and they introduced themselves to the Committee.

30. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.

31. The Chair asked all Committee members to declare any relevant interests

31.1. Mr David Chandler, Gail Coster, Dr Prithwiraj Das, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Professor Eugene Milne, Professor Sarah Parry, Pamela Rees, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Nigel Westwood and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for relapsed or refractory classical Hodgkin lymphoma.

31.2. Mr Michael Chambers declared a personal specific financial interest as he is involved currently funded by Takeda Pharmaceuticals (possible comparator company) as part of their contribution to the IMI GetReal project. The funding (now scheduled to end in Jun 2017) enables Mr Chambers to undertake general project activities, which have not been specific to any of Takeda’s medicines.

31.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

31.3. Professor Stephen O’Brien declared a non-personal non-specific financial interest as his organisation has received research funding from Bristol-Myers Squibb for clinical trials in CML.

31.3.1. It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

32. The Chair asked all NICE Staff to declare any relevant interests.

32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for relapsed or refractory classical Hodgkin lymphoma.

33. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for relapsed or refractory classical Hodgkin lymphoma.
34. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

35. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

36. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

37. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

38. Discussion on confidential information continued. This information was supplied by the company.

39. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for relapsed or refractory classical Hodgkin lymphoma.

39.1. The committee decision was based on consensus.

40. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy [ID811]

Part 1 – Open session

41. The Chair welcomed the invited experts: Angela Stainthorpe, Adrian Bagust, Sanjay Popat and Peter Clark to the meeting and they introduced themselves to the Committee.

42. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.

43. The Chair asked all Committee members to declare any relevant interests

43.1. Mr Michael Chambers, Mr David Chandler, Gail Coster, Dr Prithviraj Das Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Professor Eugene Milne, Sarah Parry, Pamela Rees, Dr Peter Selby, Professor Matt Stevenson, Nigel Westwood, Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy
43.2. Professor Stephen O'Brien declared a non-personal non-specific financial interest as his University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer, Novartis and Bristol-Myers Squibb.

9.2.1 It was agreed that this declaration would not prevent Professor Stephen O'Brien from participating in this section of the meeting.

43.3. Dr Paul Tappenden declared a non-personal specific financial interest as he provided an internal peer review of the DSU report, although he had not been directly involved.

43.3.1. It was agreed that this declaration would prevent Dr Paul Tappenden from participating in this section of the meeting.

43.4. Dr Prithwiraj Das was absent due to conflicts - a personal specific financial interest. He is employed by Boehringer Ingelheim Limited. Boehringer Ingelheim is listed as a comparator manufacturer for this appraisal.

44. The Chair asked all NICE Staff to declare any relevant interests.

44.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

45. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

45.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

46. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

47. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

48. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
49. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

50. Discussion on confidential information continued. This information was supplied by the company.

51. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy

51.1. The committee decision was based on consensus.

52. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer [ID900]**

**Part 1 – Open session**

53. The Chair welcomed the invited experts: Angela Stainthorpe, Adrian Bagust, Sanjay Popat and Peter Clark the meeting and they introduced themselves to the Committee.

54. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.

55. The Chair asked all Committee members to declare any relevant interests

55.1. Mr Michael Chambers, Mr David Chandler, Gail Coster, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Professor Eugene Milne, Sarah Parry, Pamela Rees, Dr Peter Selby, Professor Matt Stevenson, , Nigel Westwood, Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

55.2. Professor Stephen O'Brien declared a non-personal non-specific financial interest as his University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer, Novartis and Bristol-Myers Squibb

9.2.1 It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

55.3. Dr Paul Tappenden declared a non-personal specific financial interest as he provided an internal peer review of the DSU report, although he had not been directly involved.
55.3.1. It was agreed that this declaration would prevent Dr Paul Tappenden from participating in this section of the meeting.

55.4. Dr Prithwiraj Das was absent due to conflicts - a personal specific financial interest. He is employed by Boehringer Ingelheim Limited. Boehringer Ingelheim is listed as a comparator manufacturer for this appraisal.

56. The Chair asked all NICE Staff to declare any relevant interests.

56.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

57. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

57.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

58. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

59. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

60. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

61. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

62. Discussion on confidential information continued. This information was supplied by the company.

63. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

63.1. The committee decision was based on consensus.
64. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

65. Tuesday 16 May 2017 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.